Company Analysis
Sign in

Autolus Therapeutics plc (AUTL)

Nasdaq: AUTL · Biological Products, (No Diagnostic Substances) · London, GB · filing with the SEC since 2018
Full chart Alerts Compare
Grade4.3
◀ Past 3.1● Present 5.3▶ Future 4.1
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

55 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Autolus Therapeutics plc’s names, not what it holds today.

Patents granted
55
55 utility, 1976 to Dec 31, 2025
Granted in 2025
11
Against 11 in 2024 and 9 in 2023
Applications published
116
14 of them in 2025
Names they are printed under
2
a subsidiary
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology27
Medical technology17
Pharmaceuticals5
Analysis of biological materials1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
AUTOLUS LIMITED a subsidiary
named as the applicant on its applications, in GB
0 granted
114 published
AUTOLUS LIMITED a subsidiary
GB, as the owner printed on each patent
55 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 16, 202512,496,314Antigen-binding domainMedical technologyAUTOLUS LIMITED
Dec 9, 202512,492,410Engineered cytolytic immunecellBiotechnologyAUTOLUS LIMITED
Oct 28, 202512,454,578Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptorsMedical technologyAUTOLUS LIMITED
Aug 26, 202512,398,194Cell lexpressing two chimeric antigen receptors (CARs) at the cell surfaceBiotechnologyAUTOLUS LIMITED
Jun 10, 202512,325,733Binding domainBiotechnologyAUTOLUS LIMITED
May 20, 202512,304,942Cell comprising a chimeric antigen receptor or a transgenic T-cell receptor and comprising a chimeric TNF receptorMedical technologyAUTOLUS LIMITED
Apr 8, 202512,269,860Compositions and methods comprising engineered chimeric antigen receptor and modulator of CARMedical technologyAUTOLUS LIMITED
Mar 4, 202512,241,124Molecular assessment of TRBC usageBiotechnologyAUTOLUS LIMITED
Mar 4, 202512,241,068CD79-specific chimeric antigen receptorBiotechnologyAUTOLUS LIMITED
Feb 25, 202512,234,295Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereofPharmaceuticalsAUTOLUS LIMITED
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388929Retroviral and Lentiviral VectorsBiotechnologyAUTOLUS LIMITED
Dec 18, 20252025/0381224CAR T-CELLS COMPRISING AN ANTI CD33, AN ANTI CLL1 AND AT LEAST ONE FURTHER CAR ANTI CD123 AND/OR FTL3BiotechnologyAUTOLUS LIMITED
Dec 4, 20252025/0368715Chimeric Antigen ReceptorBiotechnologyAUTOLUS LIMITED
Nov 20, 20252025/0353893CellBiotechnologyAUTOLUS LIMITED
Nov 13, 20252025/0345427MethodPharmaceuticalsAUTOLUS LIMITED
Oct 30, 20252025/0333538CHIMERIC CYTOKINE RECEPTORPharmaceuticalsAUTOLUS LIMITED
Oct 30, 20252025/0333505T-CELL RECEPTOR CONSTANT REGION 1 ANTIBODY OR T-CELL RECEPTOR CONSTANT REGION 2 ANTIBODYAnalysis of biological materialsAUTOLUS LIMITED
Oct 9, 20252025/0314655METHODSMedical technologyAUTOLUS LIMITED
Sep 25, 20252025/0296976COMPOSITIONS AND METHODS COMPRISING ENGINEERED CHIMERIC ANTIGEN RECEPTOR AND MODULATOR OF CARMedical technologyAUTOLUS LIMITED
Sep 18, 20252025/0289891ANTI-CD307E SINGLE-DOMAIN ANTIBODIES, USES THEREOF IN CAR T-CELL AND FOR THE TREATMENT OF DISEASESMedical technologyAUTOLUS LIMITED
What it applied for, 2024 to 2025: Biotechnology 15 · Medical technology 8 · Pharmaceuticals 2 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AUTL · research, not advice